Technology Bundle ID
TAB-2699

Nucleic Acid-based Differentiation and Identification of Medically Important Fungi

Linked ID
E-332-2013-0
Lead Inventors
Christine Morrison (CDC)
Mark Lindsley (CDC)
Co-Inventors
Jong Soo Choi (CDC)
Zhenyu Qin (CDC)
Development Stages
Pre-Clinical (in vitro)
Development Status
In vitro data available
ICs
CDC
This invention, entailsnucleic acid-based assays, for detecting the presence of pathogenic fungi such as Histoplasma capsulatum, Blastomyces dermatitidis, Coccidioides immitis, Pneumocystis brasiliensis, and/or Penicillium marneffei within a sample. Within a healthcare setting, this particular approach can greatly reduce pathogen identification time, better direct treatments and ultimately improve patient outcomes. Further, this technology provides improved diagnostic specificity compared to serologic tests for circulating antibodies using patient serum samples- an approach that may give particularly aberrant results for immunosuppressed individuals, and who are frequently afflicted with opportunistic fungi. This technology is readily adaptable as kits used for species-specific identification of fungal pathogen infections and environmental contamination.
Commercial Applications
  • Directing antifungal drug therapy for improved patient outcomes
  • Detection, discrimination of fungal pathogens
  • Addressing secondary infections of immunosuppressed individuals or asthmatics
Competitive Advantages
  • Rapid, sensitive, simple and specific
  • Potential for automation and high-throughput screening
  • Easily adaptable to kit form

Request More Info

Licensing Contact: